Main Article Content
Streptococcus pneumonia (also known as pneumococcal) is a commensal that colonizes the upper respiratory tract and a pathogen that causes intrusive illnesses like otitis media, pneumonia, sepsis, and meningitis. In India, the Invasive Bacterial Infection Surveillance (IBIS) organization and South Asian Pneumococcal Alliance (SAPNA) have been associated with assortment of significant information in regards to serotype dissemination and antimicrobial obstruction of pneumococcal diseases for over 12 years. COVID 19 Patients are much more prone towards this infection, if untreated at appropriate time. So development of New Device are immense Important which contributes rapid and Proper Drug Delivery to lungs. Research must be carried out in the field of Novel Drug Delivery System for target delivery of Drugs like Antibiotic, Bronchodiator and Corticosteroid to Respiratory Tract. The present Review article focus Different grade of Pneumococcal Infection and Infection associated with Post COVID Condition. The article also highlights new devices which helpful for Pulmonary drug delivery which is vital during COVID Associated Pneumococcal Infection.
Bennet JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Eighth edition (Philadelphia: Elsevier Saunders); 2015.
Ganaie F, Saad JS, Mcgee L, Van Tonder AJ, Bentley SD, Lo SW, et al. A new pneumococcal capsule type, 10D, is the 100th Serotype and Has a Large. MBio. 2020;11(3):e00937–e00920. DOI: 10.1128/mBio.00937-20
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: Transmission, colonization and invasion. Nat. Rev. Microbiol. 2018;16:355–367. DOI: 10.1038/s41579-018-0001-8
Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154. [PubMed] [Google Scholar]
Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A: The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012;21:57-65.
World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed; 2017. Available:https://www.who.int/newsroom/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-newantibiotics-are-urgently-needed (Accessed September 28, 2020).
Kim SH, Song JH, Chung DR, Thamlikitkul V, Yang Y, Wang H, et al. Ansorp study group changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian Countries: An Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Antimicrob. Agents Chemother. 2012;56:1418–1426. DOI: 10.1128/AAC.05658-11.
Kim L, Mcgee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: A United States perspective. Clin. Microbiol. Rev. 2016;29:525–552. DOI: 10.1128/CMR.00058-15
Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Effificacy of pneumococcal vaccination in adults. a Meta-Analysis of Randomized Controlled Trials. Arch. Intern. Med. 1994;154: 2666–2677. DOI: 10.1001/archinte.1994.00420230051007
Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of Pneumococcal Conjugate Vaccination of Infants on Pneumonia and Inflfluenza Hospitalization and Mortality in All Age Groups in the United States. MBio. 2011;2(1):e00309–e00310. DOI: 10.1128/mBio.00309-10
Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-Specifific Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Pneumococcal Pneumonia in Adults Aged 65 Years or Older: A Multicentre, Prospective, Test-Negative Design Study. Lancet Infect. Dis. 2017;17:313–321. DOI: 10.1016/S1473-3099(17)30049-X
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health d the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264e6.
Lai MM, Holmes KV. Coronaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott-Raven; 2001
Shaylika Chauhan. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomedical Journal DOI:https://doi.org/10.1016/j.bj.2020.05.023
Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259e60.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet; 2020.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497e506.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. DOI: 10.1016/S0140-6736(20)30183-5
Zhang BZ, Chu H, Han S, Shuai H, Deng J, Hu YF, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30:928–31. DOI: 10.1038/s41422-020-0390-x
Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. JAMA Neurol. 2020; 77:683–90. DOI: 10.1001/jamaneurol.2020.1127
Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020 Jul;108(1):17-41.
Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, O'Mahony L, Gao Y, Nadeau K, Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020 Jul;75(7):1564-1581
Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020 Jul;20(7):389-391
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 Jul 09;383(2):120-128
van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Brüggemann RJ, van der Hoeven H. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020 Apr 27;9
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020 March-April;34(2):327-331
Peter M George, Shaney L Barratt, Robin Condliffe, Sujal R Desai, Anand Devaraj, Ian Forrest, Michael A Gibbons, Nicholas Hart, R Gisli Jenkins, Danny F McAuley, Brijesh V Patel, Erica Thwaite, Lisa G Spencer Respiratory follow-up of patients with COVID-19 pneumonia, State of the art review , George PM, et al Thorax. 2020;75:1009–1016. DOI:10.1136/thoraxjnl-2020-215314
Patil JS, Sarasija S, Pulmonary drug delivery strategies: A concise, systematic review, Lung India. Jan - Mar 2012;29(1):44-49.
Bivas-Benita M, Zwier RI, Junginger HE, Borchard G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur. J. Pharm. Biopharm. 2005;61(3):214 –218.
Basavaraj K. Nanjwade, Sagar A. Adichwal, Kishori R. Gaikwad, Kemy A. Parikh, Manvi FV. Pulmonary drug delivery: Novel pharmaceutical technologies breathe new life into the lungs, PDA Journal of Pharmaceutical Science and Technology. 2011;65:513-534.
Evans CM, Koo JAS. Airway mucus: the good, the bad, the sticky. Pharmacol Therapeut 2009;121:332-48.
Palecanda A, Kobzik L. Receptors for unopsonized particles: The role of alveolarmacrophages scavenger receptors. Curr Molecul Med. 2001;1:589-95.
Lizio R, Klenner T, Borchard G, Romeis P, Sarlikiotis AW, Reissmann T, et al. Delivery of the GnRH antagonist centrolix by intratracheal instillation in Anesthetized rats. Eur J Pharm Sci. 2000;9:253-8
Gangurde HH, Chordiya MA, Baste NS, Tamizharasi S, Upasani CD. Approaches and devices used in pulmonary drug delivery system: a review. Asian Journal of Pharmaceutical Research and Health Care. 4(1):11-27
Mark M. Bailey, Cory J. Berkland. Nanoparticle formulations in pulmonary drug delivery. Medicinal Research Reviews. 2009;29(1):196-212.
Chan HK. Inhalation drug delivery devices and emerging technologies. Expert Opin Ther Patents. 2003;13:1333-43.
Telko, M. J.; Hickey, A. J. Dry powder inhaler formulation. Respiratory Care 2005, 50 (9), 1209 –1227.
Mariam Ibrahim Rahul Verma Lucila Garcia-Contreras. Inhalation drug delivery devices: technology update, Medical Devices: Evidence and Research. 2015;8.
Freitas JRA. What is nanomedicine? Nanomed Nanotechnol Biol Med. 2005;1(1):2–9.
Basu P. Technologies that deliver. Nat Med 2003;9(9):1100–1101
Lee VHL. Nanotechnology: Challenging the limit of creativity in targeted drug delivery. Adv Drug DelivReV 2004;56(11):1527–1528.
Nishikant C. Shinde, Nisha J. Keskar, Prashant D. Argade. Nanoparticles: Advances in drug delivery systems. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2012;3(1). ISSN: 0975-8585,922-929